Physician profile
Jared M Kusar
NPI 1720548993
$1,739.65
in general payments reported to CMS, 2019-2025
24 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $346 · 2023: $1,072 · 2024: $132 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338 · Debt Forgiveness: $56.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.73 |
| Debt Forgiveness | $56.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.92 | 2022-2024 | Jardiance, Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $169.84 | 2022-2023 | Farxiga, Breztri |
| Pfizer INC. | $138.90 | 2022-2024 | |
| Abbott Laboratories | $135.86 | 2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $130.27 | 2023-2025 | Camzyos |
| Glaxosmithkline, LLC. | $104.82 | 2022 | |
| Astellas Pharma US INC | $68.09 | 2023 | Veozah, Myrbetriq |
| Baxter Healthcare | $56.23 | 2023 | |
| Xeris Pharmaceuticals, INC. | $55.95 | 2022-2024 | Gvoke Hypopen |
| Novo Nordisk INC | $54.80 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $51.18 | 2022 | |
| Exact Sciences Corporation | $39.70 | 2023-2024 | Cologuard Collection Kit |
| Cvrx, INC. | $36.61 | 2025 | Barostim Neo System |
| Idorsia Pharmaceuticals US INC | $31.87 | 2022-2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.95 | 2022-2024 | Prolia, Evenity |
| Dexcom, INC. | $20.89 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $19.94 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $15.34 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.64 | 2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $14.58 | 2023 | |
| Lundbeck LLC | $13.76 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Kusar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.